While most cell types experience a functional decline after years of proliferation and replication, T cells can proliferate seemingly indefinitely and without detriment.Â
Nutcracker Therapeutics Inc., a biotechnology company focused on developing RNA therapies through its proprietary technology platform, presented a poster on NTX-472, its new preclinical drug candidate for B cell lymphoma, at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago.
Scientists at UC Davis Comprehensive Cancer and the UC Davis Department of Radiology have discovered a novel way to image the unique blood supply of the lungs. Their findings, published in the Journal of Nuclear Medicine, suggest the new method could help determine if lung cancer treatment is working.
Robotic liver surgery can be a safe outpatient procedure, according to a study published in the Journal of the American College of Surgeons. In fact, 8% of the patients sampled in the analysis were discharged to go home on the same day.
For nearly two decades, how kidney cancer becomes resistant to rapalog drugs has baffled the scientific community. Now, a study by researchers at UT Southwestern Medical Center’s Kidney Cancer Program sheds light.Â
Cosylab, a provider of control systems and software solutions for complex and precise machines, has entered into a collaboration with Mayo Clinic to advance cancer care in the United States and beyond.Â
The University of Texas MD Anderson Cancer Center and Sibylla Biotech announced a strategic collaboration agreement to discover and develop novel small-molecule cancer therapies known as folding interfering degraders, which disrupt the proper folding of target proteins and lead to their degradation.
Atlantic Health System, an integrated health care system setting standards for quality health care, and Mevion Medical Systems, the leading provider of compact single-room proton therapy systems, have announced Atlantic Health System’s plans to acquire and install a MEVION S250-FIT Proton Therapy System at the Carol G. Simon Cancer Center.Â
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center and the IU School of Medicine have discovered that Black patients with breast cancer who are treated with docetaxel experience less peripheral neuropathy. Their findings represent an important shift in knowledge about a patient population who’ve historically been underrepresented in breast cancer research.
Data from the IMROZ phase III trial demonstrated Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide and dexamethasone followed by Sarclisa-Rd (the IMROZ regimen) significantly reduced the risk of disease progression or death by 40%, compared to VRd followed by Rd in patients with newly diagnosed multiple myeloma not eligible for transplant.Â
